1 / 22

Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice

Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice. Janet Kelly, Pharm.D., BC-ADM February 24, 2004. Health Care Cost Over Time. Factors Contributing to Increasing Medication Costs. Clinical Pharmacists. Outcomes & Cost Management. Formulary Management. Providers

kioko
Download Presentation

Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004

  2. Health Care Cost Over Time

  3. Factors Contributing to Increasing Medication Costs

  4. Clinical Pharmacists Outcomes & Cost Management Formulary Management Providers (RN, MD, etc)

  5. What is a Drug Formulary? • List of Drugs Which May Be Prescribed • Developed by the P&T Committee based on: • Efficacy • Safety • Cost Effectiveness • Therapeutic Equivalency • Treatment Guidelines

  6. How Can a Formulary Optimize Outcomes & Costs? • Standardization of Care • Appropriate Utilization • Improved Safety • Less Potential for Errors • Bulk Purchasing • Contract Pricing

  7. Role of Clinical Pharmacists in Outcomes & Cost Management • Identification • Reality Check • Expertise • Implementation

  8. Therapeutic Equivalency Therapeutic Equivalency UW Medicine Example: 5HT3 Antagonists Ondansetron (Zofran) Dolasetron (Anzemet) Granisetron (Kytril)

  9. Equipotent Dosing IV Dosing Ondansetron 8mg Dolasetron 100mg Granisetron 1mg = = Oral Dosing Ondansetron 16mg Dolasetron 100mg Granisetron 2mg = =

  10. Treatment Guidelines For Chemotherapy Induced Nausea/Vomiting

  11. Cost Savings Associated with the 5HT3 Program at UW Medicine Net Savings = $534,000

  12. New Drug Evaluation for Formulary • CLINICAL EFFICACY • Therapeutically superior to current formulary options • Effective for the treatment of condition which previously had no effective therapy • SAFETY • Improved safety and/or tolerability compared • to current therapeutic options while maintaining • therapeutic effectiveness • COST EFFECTIVENESS • Offers cost advantages to the institution for a given • outcome compared to current formulary options

  13. How is Cost Effectiveness Defined? Therapeutic Outcomes Therapeutic Outcomes & Economic Evaluation = Cost Per Outcome

  14. Steps in an Economic Evaluation • Determination of Total Cost • Determination of Reimbursement • Calculation of Potential Revenue

  15. Darbepoetin: Formulary Evaluation • Clinical Evaluation (compared to Epoetin) • Similar efficacy with less frequent dosing ? Equivalent dosing ? Dose escalation • Similar safety ? Improved compliance

  16. Economic Evaluation of Darbepoetin Determination of Costs: Drug Acquisition Rebates and Incentives for Other Amgen Products Convenience Less frequent administration Dollar Value ? Drug Administration Cost Clinic vs. Self Administered

  17. Economic Evaluation of Darbepoetin Determination of Reimbursement: Ambulatory vs. Hospitalized Insurance Mix % Medicare, Medicaid, & Private Patient Responsibility Co-pays

  18. Economic Evaluation of Pegfilgrastim Calculation of Profit Margin: - Total Cost Reimbursement = Profit Margin

  19. UW Medicine Clinical Pathway for Darbepoetin for Anemia of CRI Hgb<11 g/dL Hgb<11 g/dL Check nutritional cofactors GOALS OF DARBEPOETIN THERAPY Resolution of Anemia : Hgb=12 g/dL Previously untreated pts 0.9 mcg/kg q 2 weeks* Previously untreated pts 0.9 mcg/kg q 2 weeks 2 week Follow Up Has Hgb Increased > 1g/dl over baseline? 2 week Follow Up Has Hgb Increased > 1g/dl over baseline? • Supplement with iron if: • Serum ferritin<100 mg/ml • Transferrin saturation<20% Yes No Continue Therapy NO DOSE INCREASE Continue Therapy NO DOSE INCREASE Decrease Dose by 25% Decrease Dose by 25% 6 week Follow Up Has Hgb> 1g/dl from baseline? 6 week Follow Up Has Hgb> 1g/dl from baseline? No Yes Recheck nutritional cofactors Recheck nutritional cofactors Increase dose to next vial size Maximum of 200 mcg q 2 weeks Increase dose to next vial size Maximum of 200 mcg q 2 weeks Continue Therapy If Hgb>12 decrease dose to next vial size Continue Therapy If Hgb>12 decrease dose to next vial size

  20. UW Medicine – Clinical Pathway for Darbepoetin use in Chemotherapy Induced Anemia Hgb<11 g/dL Hgb<11 g/dL GOALS OF DARBEPOETIN THERAPY Resolution of Anemia : Hgb>12 g/dL Reduced need for transfusion Starting Dose: 200 mcg q2 wk or 300 mcg q 3wk • Supplement with iron if: • Serum ferritin<100 mg/ml • Transferrin saturation<20% 2 week Follow Up Has Hgb Increased > 1g/dl over baseline? 6 week Follow Up Has Hgb Increased > 1g/dl over baseline? Yes No Recheck nutritional cofactors Increase dose to 300 mcg q 2 wks Continue Therapy Yes 6 week Follow Up Has Hgb> 1g/dl from baseline? 12 week Follow Up Has Hgb> 1g/dl from baseline? No Recheck nutritional cofactors Recheck nutritional cofactors Consider discontinuing - Depending on Pt’s symptomatic response Monitor Hgb –hold if Hgb>13 Resume Tx when Hgb<12 200 mcg q3wks

  21. Comparison of Cost Effectiveness Darbepoetin vs. Epoetin Therapeutic Outcome Equivalent & Economic Evaluation Beneficial = Cost Per Outcome Decreased

  22. Darbepoetin Added to Formulary With Usage Guidelines Economic Impact at 6 months: No Absolute Cost Savings (# Pts) Relative Cost Savings $250,000 Drug Usage Evaluation Results: Response Rate only 61% Inadequate Monitoring of Iron Stores Doses given when not anemic

More Related